Holen Sie sich die Stockscreener-App
0.905
0.11%
-0.001
Vorhandelsmarkt:
.89
-0.015
-1.66%
Xilio Therapeutics Inc Aktie (XLO) Neueste Nachrichten
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short Interest - Defense World
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Xilio's Novel Immunotherapy Platform Transform Cancer Treatment? CEO Reveals Latest Progress - StockTitan
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 12.3% – Here’s What Happened - Defense World
Xilio (XLO) Stock Zooms 125% Higher On Cancer Fighting Deal with AbbVie - MSN
Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie - Global Legal Chronicle
Abbvie Inc. Reports 9.0 % Passive Stake In Xilio Therapeutics, Inc. As Of Feb 11SEC Filing - Marketscreener.com
Top Biotech Stocks To Keep An Eye OnFebruary 12th - MarketBeat
Stock summary: Xilio Therapeutics ended the week with a surge of 70.12% - Business Upturn
Latham Advises AbbVie on Collaboration and Option Agreement With Xilio Therapeutics and Related Equity Investment - Latham & Watkins LLP
Xilio shares soar on AbbVie collaboration deal - MSN
AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn - PMLiVE
Top Biotech Stocks To Keep An Eye On – February 12th - Defense World
AbbVie Deal Unmasks Promise Of Xilio’s T-Cell Engagers - News & Insights
Xilio advances masked T-cell engagers targeting PSMA, CLDN18.2 and STEAP1 - BioWorld Online
Xilio Therapeutics: Innovative TCE Platform and Strategic AbbVie Partnership Justify Buy Rating - TipRanks
AbbVie and Xilio Therapeutics announce collaboration and option agreement - MSN
We're Hopeful That Xilio Therapeutics (NASDAQ:XLO) Will Use Its Cash Wisely - Simply Wall St
Petri Dish: a new AbbVie deal, layoffs, and CFO departures - The Business Journals
AbbVie partners with Xilio to develop tumour-activated immunotherapies - World Pharmaceutical Frontiers
AbbVie and Xilio to collaborate on antibody-based immunotherapies - Yahoo Finance
AbbVie Stock: $2.1B Cancer Therapy Deal Boosts Portfolio - sharewise
Xilio Gains 125% on New Deal with AbbVie to Target Prostate and Other Cancers - PUNE.NEWS
AbbVie pens another T cell engager deal, this time with Xilio - Endpoints News
AbbVie Triples Down on T Cell Therapies in Xilio Deal Worth Up to $2.1B - BioSpace
Xilio soars after tie-up with AbbVie to develop cancer treatments - TradingView
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? - Benzinga
Stock market today: Spire Global plunged by 48.97% while Xilio Therapeutics surged by 102.16% in early trading - Business Upturn
AbbVie inks another billion-dollar oncology deal - Crain's Chicago Business
AbbVie, Xilio Hook up - Baystreet.ca
AbbVie expands oncology R&D with Xilio deal - The Pharma Letter
Xilio Therapeutics, Intel, Lithia Motors - TradingView
Xilio Therapeutics Shares Surge Premarket on AbbVie Deal -February 12, 2025 at 08:42 am EST - Marketscreener.com
Abbvie and Xilio Therapeutics, Inc. Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies - Marketscreener.com
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal - Fierce Biotech
Xilio Therapeutics Partners with AbbVie for Immunotherapy Expansion - TipRanks
Xilio shares soar on AbbVie collaboration deal By Investing.com - Investing.com Nigeria
AbbVie and Xilio Therapeutics announce collaboration - TipRanks
Abbvie And Xilio Therapeutics Announce Collaboration -February 12, 2025 at 07:51 am EST - Marketscreener.com
AbbVie and Xilio partner for tumor-activated therapies - Investing.com
Xilio Therapeutics Announces Collaboration with AbbVie to Advance Novel Tumor-Activated Immunotherapies with $52 Million Upfront Payment - Nasdaq
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs - GlobeNewswire
Major Biotech Partnership: Xilio Secures $52M AbbVie Deal with Massive $2.1B Milestone Potential - StockTitan
Major Cancer Breakthrough: AbbVie Invests $52M in Xilio's Revolutionary Tumor-Fighting Technology - StockTitan
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies - PR Newswire
RNA Based Therapeutic Market Size Expected to Reach USD 40.81 Bn by 2034 - GlobeNewswire Inc.
Allarity Therapeutics (NASDAQ:ALLR) and Xilio Therapeutics (NASDAQ:XLO) Financial Contrast - Defense World
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
3.13%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):